- $20.93bn
- $32.87bn
- $14.30bn
Viatris beats first-quarter estimates on China strength, branded drug sales
Viatris Q1 revenue beats analyst estimates on China strength
Brief: Viatris Q1 Adjusted EPS USD 0.59 Vs. IBES Estimate USD 0.5
Brief: Viatris Announces Chief Financial Officer Transition
Teva must face Mylan lawsuit over generic competition for Copaxone
Focus: Patients scramble to find estrogen patches as shortage worsens after US FDA champions use
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla
U.S. STOCKS ON THE MOVE-Energy firms, Cencora, Stryker
Viatris rises after Japan approves anxiety disorder drug
Health Rounds: Blood test improves detection of endometriosis
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research
U.S. STOCKS ON THE MOVE-Agricultural stocks, Papa John's, Oil companies
U.S. STOCKS ON THE MOVE-Nebius, Scienture, Clearmind
Viatris rises as it teams up with GoodRx to offer discounts on brand‑name drugs
U.S. STOCKS ON THE MOVE-Enovis, Cheniere, Packaging Corp of America
U.S. STOCKS ON THE MOVE-Qnity, J.M. Smucker, Vistra
Viatris forecasts 2026 profit below estimates on India manufacturing woes
Viatris falls on downbeat 2026 profit forecast